390 related articles for article (PubMed ID: 22842506)
1. Current approaches to anticoagulation for reducing risk of atrial fibrillation-related stroke.
Sanoski CA
J Pharm Pract; 2013 Jun; 26(3):204-13. PubMed ID: 22842506
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.
Burnett A; Tiongson J; Downey R; Mahan CE
Expert Opin Pharmacother; 2013 Jun; 14(9):1119-33. PubMed ID: 23574619
[TBL] [Abstract][Full Text] [Related]
4. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice.
Wittkowsky AK
Am J Manag Care; 2004 Oct; 10(10 Suppl):S297-306; discussion S312-7. PubMed ID: 15605700
[TBL] [Abstract][Full Text] [Related]
5. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
7. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
von Schéele B; Fernandez M; Hogue SL; Kwong WJ
Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
9. Role of new drugs for management of atrial fibrillation.
Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
[TBL] [Abstract][Full Text] [Related]
10. Atrial fibrillation: stroke prevention in older adults.
Quinn GR; Fang MC
Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
Lang NN; Connelly DT
J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
[TBL] [Abstract][Full Text] [Related]
12. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
Thromb Haemost; 2009 May; 101(5):938-42. PubMed ID: 19404548
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of atrial fibrillation and stroke prevention.
Bushnell CD; Matchar DB
Am J Manag Care; 2004 Apr; 10(3 Suppl):S66-71. PubMed ID: 15152748
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation.
Hickey K
Heart Lung; 2012; 41(2):146-56. PubMed ID: 22047781
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
17. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
[TBL] [Abstract][Full Text] [Related]
18. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Agarwal S; Hachamovitch R; Menon V
Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
